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Learning Objectives 
• Review morbidity, mortality and cost data for obesity and 
for bariatric surgery (is it safe and does it work?) 
• Discuss who should be referred and when (and some 
potential barriers) 
• Describe currently available surgical treatments  
• Discuss expected weight loss and resolution of 
comorbidities 
• Discuss early and late complications 
• Recommendations for the primary care provider 
 
Only 2% of patients who are eligible for 
bariatric surgery are ever referred. 
 
Why? 
 
 
 
 
Is It Safe and Does it Work? 
Quick Review: Current Morbidity, 
Mortality and Cost Data for Morbid Obesity 
• Obese individuals have a 10-50% increased risk of death compared to 
individuals of a healthy weight 
• Obese individuals spend 40% more on health care than individuals of 
normal weight 
• Risk of death from bariatric surgery is about 0.1%, major complications 
2% 
• Risks of living with morbid obesity outweigh the risks of bariatric 
surgery 
• Average cost for laparoscopic Roux-en-Y gastric bypass $25-$35,000 
• “Pays for itself” in 2-4 years time (insurance costs) 
 
 
 
Source: ASMBS 
Quick Review: Long-Term Effectiveness of 
Bariatric Surgery 
• Maximum weight loss 1-2 years after surgery; maintained at 60% 
excess body weight lost (EBWL) > 5 yrs 
• Patients may lose 30 to 50% of excess weight 6 months after surgery 
and 77% of excess weight as early as 12 months after surgery  
• Gastric bypass resolves or improves Type 2 diabetes in nearly 90% of 
patients 
• Cuts risk of developing coronary heart disease in half 
• Resolves obstructive sleep apnea in more than 85% of patients 
• Patients may improve life expectancy by 89% and decrease risk of 
premature death by 30 - 40% 
Source: ASMBS 
Christou et al. Annals of Surgery 2004 “Surgery 
Decreases Long-term Mortality, Morbidity, and 
Health Care Use in Morbidly Obese Patients” 
• Observational study of morbidly obese patients without associated 
medical conditions. 
• Followed matched surgical and non-surgical groups for 5 years to 
compare incidence of new medical conditions, hospitalizations, LOS 
and physician visits, and mortality in each cohort. 
• Significant relative risk reduction in incidence of disease seen for 10/12 
organ systems in surgery group 
• 89% relative risk reduction in mortality in the surgery group  
• 50% more hospitalizations and 45% higher direct health care costs in 
non-surgery group 
Resolution of Co-Morbidities After Bariatric 
Surgery: Diabetes, Hypertension and Sleep 
Apnea 
• Buchwald et al. JAMA 2004 “Bariatric surgery: a systematic 
review and meta-analysis” 
• 22,094 patients who underwent bariatric surgery 1990-2003.  
• Diabetes completely resolved:76.8%; Resolved or improved 
86.0%.  
• Hyperlipidemia improved: >70% 
• Hypertension resolved: 61.7%; Resolved or improved: 78.5%.  
• OSA resolved 85.7%; Resolved or improved: 83.6% 
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Resolution of Co-Morbidities After Bariatric 
Surgery: Type II Diabetes and Cardiovascular 
Risk Factors 
• Schauer et al. NEJM 2012 “Bariatric Surgery vs. Intensive Medical 
Therapy in Obese Patients with Diabetes 
• 150 pts with uncontrolled DMII randomized to surgery vs. intensive 
medical tx 
• Intensive medical tx: lifestyle counseling, wt mgmt, hypoglcemic agents 
and anti-hypertensives to achieve SBP< 130mm Hg, DBP < 80 mm Hg, 
LDL < 100 mg dL 
• 12 month primary endpoint of HbA1c < 6% achieved in 42% of gastric 
bypass and 12% of intensive medical therapy group 
• Secondary endpoints of improvement in HDL and triglycerides, body 
weight/BMI and number of hypoglycemic, lipid-lowering and anti-
hypertensive medications all significantly decreased in surgery group 



A PATIENT STORY USING A RISK 
ASSESSMENT CALCULATOR 



Pt DD: Pre-Operative Heart Attack and Stroke Risk 
Pt DD: 9 Months Post-Operative Heart Attack and Stroke 
Risk 
Resolution of Diabetes after Bariatric Surgery: My 
patient JN 
JN: Medications Pre-Surgery; BMI 46 
• Asthma: 
– Albuterol, fluticasone-salmeterol, 
montelukast 
• Hypertension: 
– Furosemide, carvedilol, lisinopril 
(Indications: Diabetic Nephropathy, 
Hypertension) 
• Diabetes 
– Glimepiride 4mg, metformin 
2000mg/day, insulin glargine 
(LANTUS) 40 units/day, insulin lispro 
(HUMALOG) 18 units/day 
• Other: Omeprazole, sumatriptan, calcium 
carbonate-vitamin D, citalopram 
JN: Medications 6 mos post-op; BMI 32 
• Asthma: 
– Albuterol, fluticasone-salmeterol, 
montelukast Rom air walking desat 
greatly improved 
• Hypertension: 
– Carvedilol, lisinopril (Indications: 
Diabetic Nephropathy, Hypertension) 
• Diabetes: No medications since 
surgery. HbA1c 6.4 to 5.8, BMI 46 to 
32 
• Other: Omeprazole, sumatriptan, calcium 
carbonate-vitamin D, citalopram, B-12, B-
complex, iron 
 
Before BMI 37 After BMI 25 
Pre-op Hgb A1c 7.8%  
on medication for diabetes, hypertension and hyperlipidemia 
Triglycerides 2112 
1 year post/op Hgb A1c=5.7%          
Trig= 118 
Off all medications 
Another Patient 
Barriers to Surgical Referral 
• Old information about safety and efficacy? 
• Continued bias/blame about calories in=calories out? 
• Stigmatization of failure-yours and your patient’s? 
• Things I hear: “My doctor didn’t want me to have the 
surgery”, “My doctor never even brought up my weight” 
• We’re on the verge of a (medical, diet, public health) 
breakthrough??? 

Patients are being denied access to the single most 
effective treatment for obesity and obesity related 
disease 
• Do I wish we had a non-surgical method that worked just as 
well?  
• Of course!  
• Are we going to find it in your patient’s lifetime? 
• A multidisciplinary approach includes surgery at this point 
in history 
 
Referring the Right Patient at the Right 
Time 
• How long do you wait before telling patients this is an 
option? 
• The patients I see have been battling their weight for 10, 20, 
30 years and more. How about your patients? 
• They are riddled with guilt, shame, frustration, desperation 
and see resorting to surgery as a culmination of a lifetime of 
failure 
• Lifelong flogging…is it healthy? 
 
“You didn’t fail. We have failed you.” 
 
Source: Behavioral Risk Factor Surveillance System, CDC. 
Obesity Trends* Among U.S. Adults 
BRFSS, 2003 
(*BMI ≥30, or ~ 30 lbs. overweight for 5’ 4” person) 
No Data          <10%           10%–14%     15%–19%           20%–24%          ≥25% 
Source: Behavioral Risk Factor Surveillance System, CDC. 
Prevalence* of Self-Reported Obesity Among U.S. Adults 
BRFSS, 2012 
*Prevalence reflects BRFSS methodological changes in 2011, and these estimates should not be compared to those 
before 2011. 
                                         15%–<20%   20%–<25%         25%–<30%         30%–<35%         ≥35%  
Source: Behavioral Risk Factor Surveillance System, CDC. 
Refer for surgical consultation 
6 mos? 
My Addition 
BMI: It’s a number, not a judgment. 
The 5 A’s of Obesity Management 
from the Canadian Obesity Network 
• Ask for permission to discuss weight and explore readiness for change  
• Assess obesity related health risk and potential “root causes” of weight 
gain  
• Advise on obesity risks, discuss benefits treatment options  
• Agree on realistic weight-loss expectations and on a SMART plan to 
achieve behavioral goals  
• Assist in addressing drivers and barriers, offer education and resources, 
refer to provider, and arrange follow-up 
 
Who Should be Referred and When? 
• Dixon: “Referral for a Bariatric Surgical Consultation: It is Time to Set 
a Standard of Care” Obes Surg 2009 
•  “risk is a continuous concept based[on much more than BMI]”  
• Referral should occur following: “A finite period (e.g., 6 months?) of 
unsuccessful combined non-surgical therapies”  
• Notes that psychologic comorbidities are highly under-investigated and 
patients who suffer from them are significantly under-referred. 
• Categorizes “ Weight-loss responsive comorbidities” (RR>5: DMII, 
HLD, OSA, IIH, Nonalcoholic steatohepatitis) to determine whether 
surgery may be indicated or is indicated. Terms obesity as a “serious 
chronic relapsing condition” 
 
 
Who and When?  
• Proposes graded levels of indications for bariatric surgery:  
• Suggests initial evaluation from comorbidity standpoint:  
– What is the strength of the relationship between the comorbidity 
and obesity? 
– How serious is the comorbidity? 
– What is the effectiveness of weight loss(or hormonal axis 
changes) for the comorbidity? 
– How effective is current therapy for the patient’s condition? 
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Who and When?  
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Too sick for surgery? 
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Surgical Referral? 
NIH Recommendations 
 (1) patients seeking therapy for severe obesity for the first time should be 
considered for treatment in a nonsurgical program with integrated components of a 
dietary regimen, appropriate exercise, and behavioral modification and support, 
 (2) gastric restrictive or bypass procedures could be considered for well-informed 
and motivated patients with acceptable operative risks,  
(3) patients who are candidates for surgical procedures should be selected 
carefully after evaluation by a multidisciplinary team with medical, surgical, 
psychiatric, and nutritional expertise,  
(4) the operation be performed by a surgeon substantially experienced with the 
appropriate procedures and working in a clinical setting with adequate support for 
all aspects of management and assessment  
(5) lifelong medical surveillance after surgical therapy is a necessity.  
 

When? 

WEIGHT LOSS OPERATIONS: 
ANATOMY, OUTCOMES AND 
COMPLICATIONS 
 
Laparoscopic Roux-en-Y Gastric Bypass 
 • Gold-standard 
• Excellent long-term weight 
loss and resolution of 
comorbidities including 
remission of diabetes in 
majority of patients 
• Complication rates are 
LOW 
• Data >30 yrs available 
 
 
Laparoscopic Sleeve Gastrectomy 
 
• Numbers growing quickly 
• Metabolic component, 
good diabetes resolution 
• Similar complication rates 
to LRYGB; leak can be 
catastrophic 
• Long-term data not 
available yet (6yr) 
 
 
Laparoscopic Adjustable Gastric Banding                                                      
• Falling out of favor (we 
no longer put them in) 
• Sleeve gastrectomy 
largely replacing 
• Approved for BMI≥30 
• High failure rate 
 
Vertical Banded Gastroplasty, Duodenal 
Switch, Jejunoileal Bypass 
Vertical Banded Gastroplasty 
Managing Complications 
Early (30-day, mostly 
surgeon) 
• Anastomotic or staple line leak 
• Hemorrhage 
• Marginal Ulcer 
• PE/MI 
• Infection 
• Dehydration #1 cause of 30-day 
readmission 
 
Late (Lifetime, Multi-
disciplinary) 
• Bowel Obstruction 
• Ulcer/Stenosis 
• Abdominal pain/ GI 
complaints 
• Malabsorption/ Malnutrition 
• Failure of weight loss 
Intestinal Obstruction 
• RYGB, VBG, other bypass 
• Internal hernia, adhesions, anastomotic problems: 0.1-9% 
(no higher than other abdominal operations) 
• Key points:  
– Presents with severe sudden abdominal pain 
– Vomiting is NOT likely to be present 
– Order imaging (CT scan) immediately 
– Conservative management does not work: surgical emergency 
Roux Limb Obstruction 
Marginal Ulcer and Stricture 
• Pain, dysphagia, nausea, vomiting 
• 3-5% 
• Endoscopy vs empiric tx 
• Check h. pylori 
• Tobacco and NSAID’s are forbidden for life with few exceptions (ASA, 
steroid bursts) and are almost always involved. Check nicotine levels 
• High dose PPI, carafate +/- triple therapy if indicated 
• Repeat endoscopy if unimproved 
• Can cause GJ stricture, similar presentation, may need surgery 
Abdominal Pain and GI Complaints 
• Dumping Syndrome 
• Diet non-compliance 
• Food intolerances 
• SIBO 
• Gallstones (13-16%) 
• Kidney stones 
• Intermittent Obstruction 
Malabsorption/ Malnutrition 
• Most common after bypass procedures 
• Iron, vitamin B12 and calcium most frequently seen 
deficiencies 
• Rates 10-15% 
• Vitamin D deficiency with metabolic bone disease remains 
common after gastric bypass so calcium and vitamin D 
levels should be monitored and replaced 
Monitoring and Supplements 
• Patients should be seen at 1, 3, 6, 12 months and annually 
thereafter 
• Screening labs each visit 
• Supplements adjusted periodically 
• Need for IM/IV supplementation rare for modern bypass 
patients 
Monitoring and Supplements 
Lap Roux-en Y Gastric Bypass (LRYGB) – Supplement Guidelines  
• chewable multivitamin complete, two (2) times daily 
• iron tablet daily  [iron 65mg]  or  [ferrous sulfate 325mg] 
• chewable or Gelcaps calcium plus vitamin D three (3) times daily   
• vitamin B12 (500 mcg) daily  
• B-Complex vitamin daily 
• 1000 IU Vitamin D daily 
Most patients after year 1 take MVI and calcium only  
 
Monitoring and Supplements 
Lap. SLEEVE Gastrectomy (LSG) - Supplement Guidelines 
• 1 chewable multivitamin complete each day.  
• 1 B12 daily 
• 1000 IU Vitamin D daily 
 
1, 3, 6 Month Screening Labs 
• Hgb 
• B12 
• Prealbumin 
• Albumin 
• Lipid panel 
• Vitamin D 
• Glucose – if indicated 
• Hgb A1C- if indicated 
 
Annual Screening Labs 
• Calcium 
• Ferritin 
• Folate 
• Glucose 
• Hemoglobin 
• Hemoglobin A1c 
• Lipid Panel 
• LFT’s 
• PTH 
• Prealbumin 
• Vitamin B1 
• Vitamin B12 
• Vitamin D 25-hydroxy 
Follow-Up 
• Short and Long-Term considerations 
– Pregnancy and infertility 
– Medications (diabetes and hypertension) 
– Lifestyle health 
– Smoking 
– Weight check 
Managing Weight Regain 
 
• Multidisciplinary, back to the drawing board 
• Review behavior 
• Rule out an anatomic problem (imaging) 
• Revisional Surgery 
 


Questions and/or Comments? 
